Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
47.49
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 01, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
April 26, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
April 23, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Expert Ratings For Apellis Pharmaceuticals
April 15, 2024
Via
Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today
April 10, 2024
Via
Benzinga
The 5 Stocks Most Sold By Insiders This Year
April 16, 2024
Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices.
Via
MarketBeat
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
March 29, 2024
Via
Benzinga
Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals
March 27, 2024
Via
Benzinga
Peering Into Apellis Pharmaceuticals's Recent Short Interest
March 15, 2024
Via
Benzinga
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings)
February 28, 2024
Via
Benzinga
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
March 11, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
March 06, 2024
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
Via
MarketBeat
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Here's How Much You Would Have Made Owning Apellis Pharmaceuticals Stock In The Last 5 Years
February 22, 2024
Via
Benzinga
$1000 Invested In Apellis Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
February 05, 2024
Via
Benzinga
ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
February 28, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
February 26, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
February 20, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
January 30, 2024
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday
February 05, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
January 26, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)
January 09, 2024
Via
Benzinga
Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
January 24, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
January 17, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
January 15, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.